Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine combined with hydromorphone for opioid-sparing analgesia after VATS lobectomy
ChiCTR2300070409Phase 4Not yet recruiting
- Sponsor
- Tai'an City Central Hospital
- Start
- Apr 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lidocaine and hydromorphone in postoperative pain and postoperative nausea and vomiting (PONV) (3 arms), sponsored by Tai'an City Central Hospital. Primary endpoint: Incidence of postoperative nausea and vomiting within 24 hours after surgery. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
lidocainehydromorphone
03
Conditions
postoperative painpostoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on ChiCTR2300070409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070409.